L-Arginine enriched biscuits improve endothelial function and glucose metabolism: A pilot study in healthy subjects and a cross-over study in subjects with impaired glucose tolerance and metabolic syndrome

Lucilla D. Monti, Maria C. Casiraghi, Emanuela Setola, Elena Galluccio, Maria A. Pagani, Lucio Quaglia, Emanuele Bosi, Piermarco Piatti

Research output: Contribution to journalArticle

Abstract

Objective: The aim of this study was to evaluate the effects of a new l-arginine-enriched biscuit on endothelial function, insulin sensitivity/secretion and body composition. Materials/Methods: The project was composed of two studies. The first study was an acute pilot postprandial study in 7 healthy subjects that evaluated bio-availability and vascular effects of l-arginine-enriched biscuits that contained 6.6 g l-arginine, 21.9 g carbohydrates, 3.6 g protein, 7.5 g fat and 4.3 g dietary fiber compared with placebo biscuits and 6.6 g powdered l-arginine. Subjects underwent the tests in random order, in at least 14-day intervals. The second study was a double-blind crossover study in 15 obese subjects with IGT and MS. These subjects consumed 6.6 g of l-arginine-enriched biscuits or placebo biscuits in a 1600 kcal diet. Each study period lasted 2 weeks with a 2-week washout in between. Endothelial function, glucose tolerance, insulin sensitivity and insulin secretion were evaluated at the end of each intervention period. Results: In the first study, the groups that received the l-arginine-enriched biscuits and the powdered l-arginine had similarly increased l-arginine, NOx and cGMP levels and post-ischemic blood flow (PI-BF). In both cases, these levels were significantly higher than those in the placebo biscuit recipient group. In the second study, the l-arginine-enriched biscuit recipient group displayed increased l-arginine, NOx, cGMP, PI-BF, and Matsuda index levels, whereas their circulating glucose, proinsulin/insulin ratio and fat mass were decreased compared with the placebo biscuit recipient group. Conclusions: l-Arginine-enriched biscuits with low sugar and protein content enhance endothelial function and improve glucose metabolism, insulin sensitivity and insulin secretion in subjects with IGT and MS.

Original languageEnglish
Pages (from-to)255-264
Number of pages10
JournalMetabolism
Volume62
Issue number2
DOIs
Publication statusPublished - Feb 2013

Fingerprint

Glucose Intolerance
Cross-Over Studies
Arginine
Healthy Volunteers
Glucose
Placebos
Insulin Resistance
Insulin
Fats
Proinsulin
Dietary Fiber
Body Composition
Double-Blind Method
Blood Vessels
Proteins
Carbohydrates
Diet

Keywords

  • Endothelium
  • Functional Food
  • Insulin Resistance
  • Insulin Secretion
  • l-Arginine

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

L-Arginine enriched biscuits improve endothelial function and glucose metabolism : A pilot study in healthy subjects and a cross-over study in subjects with impaired glucose tolerance and metabolic syndrome. / Monti, Lucilla D.; Casiraghi, Maria C.; Setola, Emanuela; Galluccio, Elena; Pagani, Maria A.; Quaglia, Lucio; Bosi, Emanuele; Piatti, Piermarco.

In: Metabolism, Vol. 62, No. 2, 02.2013, p. 255-264.

Research output: Contribution to journalArticle

@article{c5cd21a90bf947359e592b72676272d5,
title = "L-Arginine enriched biscuits improve endothelial function and glucose metabolism: A pilot study in healthy subjects and a cross-over study in subjects with impaired glucose tolerance and metabolic syndrome",
abstract = "Objective: The aim of this study was to evaluate the effects of a new l-arginine-enriched biscuit on endothelial function, insulin sensitivity/secretion and body composition. Materials/Methods: The project was composed of two studies. The first study was an acute pilot postprandial study in 7 healthy subjects that evaluated bio-availability and vascular effects of l-arginine-enriched biscuits that contained 6.6 g l-arginine, 21.9 g carbohydrates, 3.6 g protein, 7.5 g fat and 4.3 g dietary fiber compared with placebo biscuits and 6.6 g powdered l-arginine. Subjects underwent the tests in random order, in at least 14-day intervals. The second study was a double-blind crossover study in 15 obese subjects with IGT and MS. These subjects consumed 6.6 g of l-arginine-enriched biscuits or placebo biscuits in a 1600 kcal diet. Each study period lasted 2 weeks with a 2-week washout in between. Endothelial function, glucose tolerance, insulin sensitivity and insulin secretion were evaluated at the end of each intervention period. Results: In the first study, the groups that received the l-arginine-enriched biscuits and the powdered l-arginine had similarly increased l-arginine, NOx and cGMP levels and post-ischemic blood flow (PI-BF). In both cases, these levels were significantly higher than those in the placebo biscuit recipient group. In the second study, the l-arginine-enriched biscuit recipient group displayed increased l-arginine, NOx, cGMP, PI-BF, and Matsuda index levels, whereas their circulating glucose, proinsulin/insulin ratio and fat mass were decreased compared with the placebo biscuit recipient group. Conclusions: l-Arginine-enriched biscuits with low sugar and protein content enhance endothelial function and improve glucose metabolism, insulin sensitivity and insulin secretion in subjects with IGT and MS.",
keywords = "Endothelium, Functional Food, Insulin Resistance, Insulin Secretion, l-Arginine",
author = "Monti, {Lucilla D.} and Casiraghi, {Maria C.} and Emanuela Setola and Elena Galluccio and Pagani, {Maria A.} and Lucio Quaglia and Emanuele Bosi and Piermarco Piatti",
year = "2013",
month = "2",
doi = "10.1016/j.metabol.2012.08.004",
language = "English",
volume = "62",
pages = "255--264",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - L-Arginine enriched biscuits improve endothelial function and glucose metabolism

T2 - A pilot study in healthy subjects and a cross-over study in subjects with impaired glucose tolerance and metabolic syndrome

AU - Monti, Lucilla D.

AU - Casiraghi, Maria C.

AU - Setola, Emanuela

AU - Galluccio, Elena

AU - Pagani, Maria A.

AU - Quaglia, Lucio

AU - Bosi, Emanuele

AU - Piatti, Piermarco

PY - 2013/2

Y1 - 2013/2

N2 - Objective: The aim of this study was to evaluate the effects of a new l-arginine-enriched biscuit on endothelial function, insulin sensitivity/secretion and body composition. Materials/Methods: The project was composed of two studies. The first study was an acute pilot postprandial study in 7 healthy subjects that evaluated bio-availability and vascular effects of l-arginine-enriched biscuits that contained 6.6 g l-arginine, 21.9 g carbohydrates, 3.6 g protein, 7.5 g fat and 4.3 g dietary fiber compared with placebo biscuits and 6.6 g powdered l-arginine. Subjects underwent the tests in random order, in at least 14-day intervals. The second study was a double-blind crossover study in 15 obese subjects with IGT and MS. These subjects consumed 6.6 g of l-arginine-enriched biscuits or placebo biscuits in a 1600 kcal diet. Each study period lasted 2 weeks with a 2-week washout in between. Endothelial function, glucose tolerance, insulin sensitivity and insulin secretion were evaluated at the end of each intervention period. Results: In the first study, the groups that received the l-arginine-enriched biscuits and the powdered l-arginine had similarly increased l-arginine, NOx and cGMP levels and post-ischemic blood flow (PI-BF). In both cases, these levels were significantly higher than those in the placebo biscuit recipient group. In the second study, the l-arginine-enriched biscuit recipient group displayed increased l-arginine, NOx, cGMP, PI-BF, and Matsuda index levels, whereas their circulating glucose, proinsulin/insulin ratio and fat mass were decreased compared with the placebo biscuit recipient group. Conclusions: l-Arginine-enriched biscuits with low sugar and protein content enhance endothelial function and improve glucose metabolism, insulin sensitivity and insulin secretion in subjects with IGT and MS.

AB - Objective: The aim of this study was to evaluate the effects of a new l-arginine-enriched biscuit on endothelial function, insulin sensitivity/secretion and body composition. Materials/Methods: The project was composed of two studies. The first study was an acute pilot postprandial study in 7 healthy subjects that evaluated bio-availability and vascular effects of l-arginine-enriched biscuits that contained 6.6 g l-arginine, 21.9 g carbohydrates, 3.6 g protein, 7.5 g fat and 4.3 g dietary fiber compared with placebo biscuits and 6.6 g powdered l-arginine. Subjects underwent the tests in random order, in at least 14-day intervals. The second study was a double-blind crossover study in 15 obese subjects with IGT and MS. These subjects consumed 6.6 g of l-arginine-enriched biscuits or placebo biscuits in a 1600 kcal diet. Each study period lasted 2 weeks with a 2-week washout in between. Endothelial function, glucose tolerance, insulin sensitivity and insulin secretion were evaluated at the end of each intervention period. Results: In the first study, the groups that received the l-arginine-enriched biscuits and the powdered l-arginine had similarly increased l-arginine, NOx and cGMP levels and post-ischemic blood flow (PI-BF). In both cases, these levels were significantly higher than those in the placebo biscuit recipient group. In the second study, the l-arginine-enriched biscuit recipient group displayed increased l-arginine, NOx, cGMP, PI-BF, and Matsuda index levels, whereas their circulating glucose, proinsulin/insulin ratio and fat mass were decreased compared with the placebo biscuit recipient group. Conclusions: l-Arginine-enriched biscuits with low sugar and protein content enhance endothelial function and improve glucose metabolism, insulin sensitivity and insulin secretion in subjects with IGT and MS.

KW - Endothelium

KW - Functional Food

KW - Insulin Resistance

KW - Insulin Secretion

KW - l-Arginine

UR - http://www.scopus.com/inward/record.url?scp=84872688525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872688525&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2012.08.004

DO - 10.1016/j.metabol.2012.08.004

M3 - Article

C2 - 23040413

AN - SCOPUS:84872688525

VL - 62

SP - 255

EP - 264

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 2

ER -